Pleiotropic effects of fenofibrate: focus on type 2 diabetes mellitus
https://doi.org/10.14341/DM2014443-50
Abstract
Aims.
The aim of the present study was to investigate the role of chronic low-grade inflammation in the development of the diabetic neuropathy and the possibility of its medical treatment with fenofibrate (145 mg/day).
Materials and Methods.
This trial included 60 patients with type 2 diabetes mellitus. The serum levels of several factors were measured: tumour necrosis factor-? (TNF-?), interleukin-1? (IL-1?), interleukin-6 (IL-6), C-reactive protein (CRP), markers of oxidative stress (malondialdehyde levels), haemostasis, uric acid, glycaemic and lipid profile and the peripheral status (electromyography, total symptom score [TSS] and neuropathy impairment score in the lower limbs [NIS-LL]). Follow-up was at 24 weeks.
Results.
A significant negative correlation was found between the excitation rate of the sural nerve and levels of TNF, IL-6 and CRP (p <0.05). A number of changes were observed in the group of patients treated with fenofibrate (145 mg, daily) for 24 weeks: Levels of TNF decreased from 9.6?3.68 to 8.1?3.02 pg/ml (p <0.05), IL-6 decreased from 3.3?1.69 to 2.7?1.28 pg/ml (p <0.05), CRP decreased from 5.6?3.63 to 3.1?2.34 mg/l (p <0.05), thiobarbituric acid (TBARS) decreased from 3.1?089 to 2.6?1.21 mmol/l (p >0.05), uric acid decreased from 364?69.85 to 296.8?87.3 mmol/l (p <0.05) and fibrinogen decreased from 4.1?0.59 to 3.4?0.71 g/l (p <0.05). Improved levels of total cholesterol, triglycerides, HDL, VLDL and atherogenic index (p <0.05) were observed. Significantly increased M-wave in extensor digitorum brevis muscle was observed, from 5.25?2.31 to 6.3?3.14 mV (p <0.05). In addition, TSS changed from 9.55?1.53 to 7.28?1.26 (p <0.005) and NIS-LL changed from 10.12?2.05 to 8.24?1.68 (p <0.05).
Conclusion.
A correlation was found between EMG parameters and serum levels of inflammatory markers. Fenofibrate significantly reduced levels of inflammatory cytokines and improved lipid and purine metabolism as well as the function of the peripheral nervous system.
The aim of the present study was to investigate the role of chronic low-grade inflammation in the development of the diabetic neuropathy and the possibility of its medical treatment with fenofibrate (145 mg/day).
Materials and Methods.
This trial included 60 patients with type 2 diabetes mellitus. The serum levels of several factors were measured: tumour necrosis factor-? (TNF-?), interleukin-1? (IL-1?), interleukin-6 (IL-6), C-reactive protein (CRP), markers of oxidative stress (malondialdehyde levels), haemostasis, uric acid, glycaemic and lipid profile and the peripheral status (electromyography, total symptom score [TSS] and neuropathy impairment score in the lower limbs [NIS-LL]). Follow-up was at 24 weeks.
Results.
A significant negative correlation was found between the excitation rate of the sural nerve and levels of TNF, IL-6 and CRP (p <0.05). A number of changes were observed in the group of patients treated with fenofibrate (145 mg, daily) for 24 weeks: Levels of TNF decreased from 9.6?3.68 to 8.1?3.02 pg/ml (p <0.05), IL-6 decreased from 3.3?1.69 to 2.7?1.28 pg/ml (p <0.05), CRP decreased from 5.6?3.63 to 3.1?2.34 mg/l (p <0.05), thiobarbituric acid (TBARS) decreased from 3.1?089 to 2.6?1.21 mmol/l (p >0.05), uric acid decreased from 364?69.85 to 296.8?87.3 mmol/l (p <0.05) and fibrinogen decreased from 4.1?0.59 to 3.4?0.71 g/l (p <0.05). Improved levels of total cholesterol, triglycerides, HDL, VLDL and atherogenic index (p <0.05) were observed. Significantly increased M-wave in extensor digitorum brevis muscle was observed, from 5.25?2.31 to 6.3?3.14 mV (p <0.05). In addition, TSS changed from 9.55?1.53 to 7.28?1.26 (p <0.005) and NIS-LL changed from 10.12?2.05 to 8.24?1.68 (p <0.05).
Conclusion.
A correlation was found between EMG parameters and serum levels of inflammatory markers. Fenofibrate significantly reduced levels of inflammatory cytokines and improved lipid and purine metabolism as well as the function of the peripheral nervous system.
About the Authors
Alexander Sergeevich Ametov
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
MD, PhD, Professor, Chief of the Endocrinology and Diabetology Chair
Competing Interests: The researchers report no conflicts of interest
Russian Federation
MD, PhD, Professor, Chief of the Endocrinology and Diabetology Chair
Competing Interests: The researchers report no conflicts of interest
Marina Alexandrovna Prudnikova
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Competing Interests: The researchers report no conflicts of interest
Russian Federation
MD, PhD-student at Endocrinology and Diabetology Chair
Competing Interests: The researchers report no conflicts of interest
References
1. Solomon T. Epidemiology and etiology of diabetic peripheral neuropathies. Advanced Studies in Medicine 2004;4(10G):1014-1021.
2. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. BJN 2004;92(03):347. Available from: http://www.journals.cambridge.org/abstract_S0007114504001795 doi: 10.1079/BJN20041213.
3. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. Clin. Invest. 2006;116(8):1793-1801. doi: 10.1172/JCI29069.
4. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-alpha- and Obesity-Induced Insulin Resistance. Science 1996;271(5249):665-670. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.271.5249.665 PubMed PMID: 8571133. doi: 10.1126/science.271.5249.665.
5. Ritchie SA, Ewart M, Perry CG, Connell JMC, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004;107(6):519-532. Available from: http://www.clinsci.org/cs/107/0519/cs1070519.htm PubMed PMID: 15324298. doi: 10.1042/CS20040190.
6. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes. N Engl J Med 2004;350(7):664-671. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa031314 PubMed PMID: 14960743. doi: 10.1056/NEJMoa031314.
7. Roopakala MS, Pawan HR, Krishnamurthy U. Evaluation of high sensitivity C-reactive protein and glycated hemoglobin levels in diabetic nephropathy. Saudi J Kidney Dis Transpl 2012;23(2):286-289. Available from: http://www.sjkdt.org/article.asp?issn=1319-2442;year=2012;volume=23;issue=2;spage=286;epage=289;aulast=Roopakala PubMed PMID: 22382220.
8. Nguyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol 2012. Available from: http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00170/abstract doi: 10.3389/fendo.2012.00170.
9. Yu L, Yang X, Hua Z, Xie W. Serum levels of pro-inflammatory cytokines in diabetic patients with peripheral neuropathic pain and the correlation among them. Zhonghua Yi Xue Za Zhi 2009;89(7):469-471. Available from: http://www.nlm.nih.gov/medlineplus/diabeticnerveproblems.html PubMed PMID: 19567096.
10. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009;94(6):2157-2163. Available from: http://europepmc.org/abstract/MED/19276232 PubMed PMID: 19276232. doi: 10.1210/jc.2008-2385.
11. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T, et al. Peripheral Neuropathy is Associated With Increased Serum Levels of Uric Acid in Type 2 Diabetes Mellitus. Angiology 2011;62(4):291-295. Available from: http://ang.sagepub.com/cgi/doi/10.1177/0003319710394164 doi: 10.1177/0003319710394164.
12. Purwata T. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. JPR 2011;4:169-75. Available from: http://www.dovepress.com/high-tnf-alpha-plasma-levels-and-macrophages-inos-and-tnf-alpha-expres-peer-reviewed-article-JPR PubMed PMID: 21811392. doi: 10.2147/JPR.S21751.
13. Herder C, Bongaerts BWC, Rathmann W, Heier M, Kowall B, Koenig W, et al. Association of Subclinical Inflammation With Polyneuropathy in the Older Population: KORA F4 study. Diabetes Care 2013;36(11):3663-3670. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc13-0382 doi: 10.2337/dc13-0382.
14. Аметов АС, Лысенко МА. Сахарный диабет 2 типа. Проблемы и решения. 2-издание. М: ГЭОТАР-Медиа; 2014. 463-464 с. [Ametov AS, Lysenko MA. Saharnyj diabet 2 tipa. Problemy i reshenija. 2 izdanie. Moscow: GJeOTAR-Media; 2014. 463-464 p.]
15. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia. Diabetes Care 2005;28(6):1419-1424. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.28.6.1419 PubMed PMID: 15920062. doi: 10.2337/diacare.28.6.1419.
16. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, et al. The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. Journal of the American College of Cardiology 2006;48(2):396-401. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109706012290 PubMed PMID: 16843192. doi: 10.1016/j.jacc.2006.05.009.
17. Wu T, Ou H, Chou C, Hsiao S, Lin C, Kao PC. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci 2007;37(2):158-166. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+57-88-5 PubMed PMID: 17522372.
18. Поленова НВ, Ваулин НА, Масенко ВП, Явелов ИС, Грацианский НА. Розувастатин и фенофибрат у больных сахарным диабетом 2-го типа с низким уровнем холестерина липопротеинов высокой плотности: изменения липидного состава крови и маркеров воспаления. Кардиология 2009; (2): 9-14. [Polenova NV, Vaulin NA, Masenko VP, Javelov IS, Gracianskij NA. Rosuvastatin and Fenofibrate in Patients with Diabetes and Low High Density Lipoprotein Cholesterol: Comparison of Changes of Lipid Levels and Some Markers of Inflammation. Kardiologija. 2009; (2): 9-14. Available from: http://www.athero.ru/Polenova-N2-2009.htm]
19. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism 2010;95(2):829-836. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2009-1487 PubMed PMID: 20061429. doi: 10.1210/jc.2009-1487.
20. Ghani RA, Yaakob IB, Wahab NA, Zainudin S, Mustafa N, Sukor N, et al. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. Journal of Clinical Lipidology 2013;7(5):446-453. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1933287413001955 PubMed PMID: 24079286. doi: 10.1016/j.jacl.2013.04.004.
21. Батрак ГА, Мясоедова СЕ, Келеш ОИ. Нелипидные эффекты микронизированного фенофибрата у больных сахарным диабетом 2 типа с атерогенной дислипидемией. Вестник Ивановской медицинской академии. 2013;18(3):45-49. [Batrak GA, Mjasoedova SE, Kelesh OI. Nonlipid effects of micronized phenofibrate in patients with type 2 diabetes with atherogenic dyslipidemia. Vestnik Ivanovskoj medicinskoj akademii. 2013;18(3):45-49. Available from: http://vestnik-ivgma.ru/attachments/151?locale=ru ]
Supplementary files
Review
For citations:
Ametov A.S., Prudnikova M.A. Pleiotropic effects of fenofibrate: focus on type 2 diabetes mellitus. Diabetes mellitus. 2014;17(4):43-50. (In Russ.) https://doi.org/10.14341/DM2014443-50
Views:
493
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
